| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 1109 | 2017 |
| MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed … AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ... Journal of Clinical Oncology 26 (13), 2192-2197, 2008 | 1004 | 2008 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 729 | 2015 |
| Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, A Tosoni, E Franceschi, G Sotti, G Frezza, P Amistà, ... Journal of Clinical Oncology 27 (8), 1275-1279, 2009 | 401 | 2009 |
| Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology AA Brandes, A Tosoni, F Spagnolli, G Frezza, M Leonardi, F Calbucci, ... Neuro-oncology 10 (3), 361-367, 2008 | 346 | 2008 |
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) AA Brandes, A Tosoni, G Cavallo, R Bertorelle, V Gioia, E Franceschi, ... British journal of cancer 95 (9), 1155-1160, 2006 | 283 | 2006 |
| High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib AMP Omuro, MG Kris, VA Miller, E Franceschi, N Shah, DT Milton, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 274 | 2005 |
| Glioblastoma in adults AA Brandes, A Tosoni, E Franceschi, M Reni, G Gatta, C Vecht Critical reviews in oncology/hematology 67 (2), 139-152, 2008 | 271 | 2008 |
| Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, E Franceschi, A Tosoni, F Benevento, L Scopece, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 263 | 2009 |
| Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, ... British journal of cancer 96 (7), 1047-1051, 2007 | 238 | 2007 |
| Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent … AA Brandes, A Tosoni, G Cavallo, M Reni, E Franceschi, L Bonaldi, ... Journal of clinical oncology 24 (29), 4746-4753, 2006 | 223 | 2006 |
| INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma M Van Den Bent, M Eoli, JM Sepulveda, M Smits, A Walenkamp, ... Neuro-oncology 22 (5), 684-693, 2020 | 179 | 2020 |
| Long‐term results of a prospective study on the treatment of medulloblastoma in adults AA Brandes, E Franceschi, A Tosoni, V Blatt, M Ermani Cancer 110 (9), 2035-2041, 2007 | 176 | 2007 |
| Temozolomide as salvage treatment in primary brain lymphomas M Reni, F Zaja, W Mason, J Perry, E Mazza, M Spina, R Bordonaro, ... British Journal of Cancer 96 (6), 864-867, 2007 | 175 | 2007 |
| Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments AA Brandes, E Franceschi, A Tosoni, ME Hegi, R Stupp Clinical cancer research 14 (4), 957-960, 2008 | 171 | 2008 |
| O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for … AA Brandes, E Franceschi, A Tosoni, S Bartolini, A Bacci, R Agati, ... Neuro-oncology 12 (3), 283-288, 2010 | 147 | 2010 |
| Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial M Reni, W Mason, F Zaja, J Perry, E Franceschi, D Bernardi, S Dell'Oro, ... European Journal of Cancer 40 (11), 1682-1688, 2004 | 144 | 2004 |
| Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas I Maggio, E Franceschi, A Tosoni, VD Nunno, L Gatto, R Lodi, AA Brandes CNS oncology 10 (2), CNS72, 2021 | 121 | 2021 |
| Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III M Visani, D De Biase, G Marucci, S Cerasoli, E Nigrisoli, MLB Reggiani, ... Molecular oncology 8 (2), 417-430, 2014 | 118 | 2014 |
| Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo … AA Brandes, A Tosoni, E Franceschi, V Blatt, A Santoro, M Faedi, ... Cancer chemotherapy and pharmacology 64, 769-775, 2009 | 115 | 2009 |
